Colitis Clinical Trial
Official title:
Soluble Syndecan 1 as Biomarker for Acute and Chronic Bowel Inflammation
The aim of the study is to evaluate the soluble biomarker syndecan-1 (sSdc1) taken from venous blood of patients with infectious intestinal diseases such as Clostridium difficile-associated colitis, bacterial colitis, Norovirus enteritis and Crohn´s disease or ulcerative colitis. The level of sSdc1 will be compared with disease activity in patients with active inflammation and with disease in remission. Secondary objectives were the assessment of correlation of the above-mentioned factors with the CRP value. Subjects will be volunteers. Blood will be taken as part of the routine clinical work-up after the written agreement blood and sSdc1-level will be assessed using a human-specific sSdc1 ELISA assay. In addition, the subjects are asked to answer a short questionnaire. The study is designed as a prospective, comparative cohort study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00272818 -
Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
|
||
| Completed |
NCT01369355 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
|
Phase 3 | |
| Completed |
NCT02709213 -
Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy
|
||
| Completed |
NCT00533078 -
Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies
|
Phase 2 | |
| Terminated |
NCT00184171 -
Treatment of Microscopic Colitis
|
N/A | |
| Recruiting |
NCT05333978 -
Optoacoustic Detection of Inflammation Using MSOT Device
|
N/A | |
| Not yet recruiting |
NCT06424769 -
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
|
N/A | |
| Recruiting |
NCT02768038 -
Intestinal Microbiome and Chronic Inflammatory Bowel Disease
|
||
| Recruiting |
NCT04272307 -
MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.
|
||
| Completed |
NCT05514561 -
FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms
|
||
| Completed |
NCT00072943 -
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
|
Phase 2 | |
| Recruiting |
NCT02687724 -
Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis
|
Phase 4 | |
| Completed |
NCT02647866 -
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
|
Phase 2 | |
| Completed |
NCT01326013 -
A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel
|
Phase 2 | |
| Not yet recruiting |
NCT05726396 -
A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis
|
Phase 2 | |
| Completed |
NCT05414552 -
ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
|
||
| Recruiting |
NCT04407247 -
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01369342 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
|
Phase 3 | |
| Completed |
NCT01369329 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
|
Phase 3 | |
| Terminated |
NCT00936585 -
NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease
|
N/A |